Aquavit Files Investigation of New Drug for New Botulinum Toxin
Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.
Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.
Los Angeles-based Cedars-Sinai Guerin Children's is launching program to provide surgical intervention for pediatric patients with congenital facial differences such as cleft lip and palate, craniosynostosis, ear and jaw deformities, and birthmarks.